# DEgenerative ROtator Cuff Disease and Botulinum TOXin

> **NCT05327972** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 60 (estimated)

## Conditions studied

- Degenerative Rotator Cuff Disease

## Interventions

- **DRUG:** The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).
- **OTHER:** PLACEBO

## Key facts

- **NCT ID:** NCT05327972
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-20
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05327972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05327972, "DEgenerative ROtator Cuff Disease and Botulinum TOXin". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05327972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*